ZEISS and Hamilton Thorne Join the Global Fertility Alliance

June 21, 2016 ZEISS Microscopy

New partners are joining founding members Merck, Illumina and Genea to support standardization of processes in assisted reproductive treatment laboratories

In vitro fertilization of oocyte with ZEISS Axio Vert.A1 and PlasDIC contrasting methodMerck, a leading science and technology company, today announced together with Illumina Inc., San Diego, US, and Genea Limited, Sydney, Australia, that the Global Fertility Alliance welcomed two new members. The alliance is a collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory. Effective immediately, Carl Zeiss Microscopy GmbH, Jena, Germany, an internationally leading microscopy enterprise that is part of the ZEISS Group, and Hamilton Thorne Ltd., Beverly, Massachusetts, US, a leading provider of precision laser devices and advanced image analysis systems for ART, regenerative medicine and developmental biology research markets, are joining the alliance and its quest to improve the consistency in ART laboratories worldwide. Following the announcement of the alliance’s formation at the 2015 Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE), an update on the alliance’s activities will be presented at this year’s ESHRE in Helsinki, Finland (3-6 July, 2016).

“Through our work with the fertility community, we know that ART outcomes strongly depend on routines and technologies applied in laboratories. As such, we are committed to overcoming current variation in ART practices and techniques,” explained Rehan Verjee, Chief Marketing and Strategy Officer at Merck’s biopharma business. “We are working in the alliance to support the development of global standards in ART laboratories. We understand this as a critical factor for ensuring a consistently high level of performance across centers and countries, ultimately supporting the goal of women and couples of having a baby.”

Human embryos, imaged with ZEISS Axio Observer and PlasDIC contrasting method

Seeing the importance of recognizing innovation in ART technologies, the Global Fertility Alliance was founded by Merck together with two strategic partners: Illumina, a leader in developing and commercializing systems for analysis of genetic variation and function, and Genea, a developer of innovative fertility technologies. The collaboration is part of Merck’s Fertility Technologies strategy to partner with experts in the field to address unmet needs together and support the market with innovations, with a clear focus on extending its product portfolio for the benefit of the fertility community. “ZEISS has a strong heritage in the development of specialized microscopes and we are committed to using our expertise in this field to drive the standardization of ART processes and techniques further,” commented Peter Kraemer, Director Market Segment Education & Routine at ZEISS Microscopy. “We are impressed by the alliance’s progress so far and look forward to contributing to improvements in ART practices through technology innovation.”

“As a pioneer in the field of developing instruments for the in vitro fertilization clinic, advancing the science of fertility treatment is in the DNA of our company,” said David Wolf, CEO of Hamilton Thorne. “With excellence in ART as its tenet, the goal of the Global Fertility Alliance is to drive automation and standardization in fertility laboratories worldwide to promote better outcomes for patients.”

The collaboration partners are aiming to welcome further members which share the common objectives and complement the expertise of the existing partner companies.

Meet ZEISS at the annual meeting of the European Society of Human Reproduction and Embryology

Learn more about ZEISS products and solutions for reproductive medicine

ZEISS Partners with Virtus Health for In-Vitro Fertilization (IVF)

About the Global Fertility Alliance

Recognizing the importance of innovation in ART technologies, the alliance aims to enhance progress and innovation in three ways. Firstly, the founding members aim to foster integration of multiple, leading fertility technologies. Secondly, building on this, the alliance will aim to collaborate with leading health care professionals and medical societies to develop global standards. And finally, as technologies in the fertility space are rapidly advancing, the alliance will also develop educational resources for health care professionals worldwide. These efforts will include training curricula and workshops as well as access to model labs, symposia and events at medical meetings. The Global Fertility Alliance was launched at the 31st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in June 2015. First members besides Merck were Illumina, a leader in developing and commercializing systems for analysis of genetic variation and function, and Genea, a developer of innovative fertility technologies.

 

The post ZEISS and Hamilton Thorne Join the Global Fertility Alliance appeared first on Microscopy News Blog.

Previous Article
ZEISS Announces Collaboration with ASM International
ZEISS Announces Collaboration with ASM International

ZEISS microscopes to be used for training on high precision manufacturing and materials testing techniques ...

Next Article
Innovating Energy Storage Materials using Correlative Microscopy by ZEISS
Innovating Energy Storage Materials using Correlative Microscopy by ZEISS

Professor Silke Christiansen, Freie Universität Berlin, and Helmholtz Center for Materials and Energy, talk...